Pages that link to "Q37710963"
Jump to navigation
Jump to search
The following pages link to Targeted cancer therapies in the twenty-first century: lessons from imatinib (Q37710963):
Displaying 50 items.
- Pharmacogenetics, pharmacogenomics, and individualized medicine (Q23919667) (← links)
- Opportunities and challenges for direct C-H functionalization of piperazines (Q26747277) (← links)
- Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor (Q27342948) (← links)
- Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer (Q27851720) (← links)
- Combination treatment including targeted therapy for advanced hepatocellular carcinoma (Q28077738) (← links)
- PIM1 kinase as a target for cancer therapy (Q28261162) (← links)
- Engineering control into medicine (Q30300786) (← links)
- digit-a tool for detection and identification of genomic interchromosomal translocations (Q33701551) (← links)
- Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients (Q34122737) (← links)
- Trends in the exploitation of novel drug targets (Q34205159) (← links)
- Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification (Q34404209) (← links)
- Quantitative microtiter fibronectin fibrillogenesis assay: use in high throughput screening for identification of inhibitor compounds. (Q34417202) (← links)
- Computational methods and opportunities for phosphorylation network medicine (Q34742859) (← links)
- Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy (Q35132090) (← links)
- Cancer metabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliers (Q35161318) (← links)
- Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells (Q35577635) (← links)
- Personalized genomic analyses for cancer mutation discovery and interpretation (Q35602861) (← links)
- Acute Toxicity-Supported Chronic Toxicity Prediction: A k-Nearest Neighbor Coupled Read-Across Strategy (Q35640623) (← links)
- Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors (Q35780797) (← links)
- Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record (Q35809920) (← links)
- Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies (Q36015077) (← links)
- Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils (Q36038823) (← links)
- Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma (Q36203262) (← links)
- Molecular profiling of childhood cancer: Biomarkers and novel therapies (Q36250783) (← links)
- NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers (Q36507559) (← links)
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice (Q36702588) (← links)
- Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia (Q36725262) (← links)
- Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing (Q36902969) (← links)
- Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib (Q37087238) (← links)
- Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. (Q37349748) (← links)
- The innovative medicines initiative: a public private partnership model to foster drug discovery (Q37655104) (← links)
- Translating p53 into the clinic. (Q37803120) (← links)
- Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor (Q37812614) (← links)
- The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs (Q37880903) (← links)
- Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. (Q37960141) (← links)
- Chemical proteomic strategies for the discovery and development of anticancer drugs (Q38170023) (← links)
- Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy (Q38208280) (← links)
- Cystine-knot peptides: emerging tools for cancer imaging and therapy (Q38243927) (← links)
- Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure (Q38355156) (← links)
- "Pruning of biomolecules and natural products (PBNP)": an innovative paradigm in drug discovery (Q38475630) (← links)
- Re-positioning protein-kinase inhibitors against schistosomiasis (Q38495042) (← links)
- PIM1 kinase as a promise of targeted therapy in prostate cancer stem cells (Q38719202) (← links)
- Tumour-inducing viruses (Q38977066) (← links)
- Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach (Q39024729) (← links)
- Protein Quality Control Dysfunction in Cardiovascular Complications Induced by Anti-Cancer Drugs (Q39102231) (← links)
- Genotype-selective combination therapies for melanoma identified by high-throughput drug screening (Q39226193) (← links)
- The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). (Q39401616) (← links)
- Cell surface receptor expression patterns in osteosarcoma (Q39507656) (← links)
- Approving molecularly targeted drugs: different approval processes for cytotoxic agents (Q39829792) (← links)
- Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. (Q40197692) (← links)